NCT03148535

Brief Summary

The bipolar depression patients of 18-55 years old were recruited. At the time of enrollment, the demographic, symptomatic, neuropsychological, neurobiological and genetic data was collected. After the completion of the baseline assessment and examination, the patients were given lithium carbonate or lithium carbonate combined with SSRI antidepressant treatment. Clinical evaluation was performed at 2 and 8 weeks after treatment, including the therapeutic efficacy and adverse drug reactions, and monitoring of serum lithium concentration. The patients further receive the fMRI scans after treatment for 8 weeks. Through above work, this study aimed to provide some guidance for the use of antidepressants in patients with bipolar depression.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Jun 2017

Geographic Reach
1 country

4 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 9, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 11, 2017

Completed
21 days until next milestone

Study Start

First participant enrolled

June 1, 2017

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
Last Updated

May 11, 2017

Status Verified

May 1, 2017

Enrollment Period

1.5 years

First QC Date

May 9, 2017

Last Update Submit

May 9, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • HRSD reduction ratio

    HRSD reduction ratio

    8 weeks

Study Arms (2)

lithium carbonate

EXPERIMENTAL

recieve lithium carbonate

Drug: Lithium Carbonate

lithium carbonate combined with SSRI antidepressant treatment

EXPERIMENTAL

recieve lithium carbonate combined with SSRI antidepressant treatment

Drug: lithium carbonate combined with SSRI antidepressant treatment

Interventions

bipolar depression recieve lithium Carbonate treatment

lithium carbonate

lithium carbonate combined with SSRI antidepressant treatment

lithium carbonate combined with SSRI antidepressant treatment

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • age 18-55 years old, bipolar depression

You may not qualify if:

  • other mental illness, serious somatic illnesses, MRI contradictions.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Institute of mental health, Peking University

Beijing, Beijing Municipality, 100191, China

RECRUITING

The first hospital of Hebei Province University

Shijiazhuang, Hebei, 050000, China

RECRUITING

Nanjing Brain Hospital

Nanjing, Jiangsu, 210000, China

RECRUITING

Dalian No.7 People's Hospital

Dalian, Liaoning, 116000, China

RECRUITING

MeSH Terms

Interventions

Lithium Carbonate

Intervention Hierarchy (Ancestors)

CarbonatesAlkaliesInorganic ChemicalsCarbonic AcidCarbon Compounds, InorganicLithium Compounds

Central Study Contacts

Ji-Tao Li, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Psychopharmacology Division Institute of Mental Health

Study Record Dates

First Submitted

May 9, 2017

First Posted

May 11, 2017

Study Start

June 1, 2017

Primary Completion

December 1, 2018

Study Completion

December 1, 2018

Last Updated

May 11, 2017

Record last verified: 2017-05

Data Sharing

IPD Sharing
Will not share

Locations